Fresolimumab (Anti-TGFb1)

Synonyms: GC1008

Catalog No.A2336 Purity:99%

Fresolimumab (Anti-TGFb1) is a pan-specific, recombinant, fully human monoclonal antibody directed against human transforming growth factor (TGF) beta 1, 2, and 3 with potential antineoplastic activity. MW : 145.5 KD.

Purity & Quality Control

Batch: Purity: 99% Protein concentration: 3.85mg/ml Endotoxin Level: ＜1EU/mg

Choose Selective TGF-beta/Smad Inhibitors

Name	Citation	ALK1	ALK2	ALK3	ALK4	TGFβRI/ALK5	ALK6	TGFβRII	TGF-β	Smad3	Others
SB431542	674					+
LDN-193189	230	++++	++++	+++			+++
Galunisertib (LY2157299)	177					++
LY2109761	126					++		+
SB525334	100					+++
SB505124	33				+	++
GW788388	24					+++
LY364947	49					++		+			RIPK2,CK1δ,MLK-7K
RepSox (E-616452)	66					++++
LDN-193189 2HCl	93	++++	++++	+++			+++
K02288	23	++++	++++	++			+++
LDN-214117	4		++
SD-208	20					++
Vactosertib (TEW-7197)	21				+++	+++
ML347	5	++	++
LDN-212854	7	++++	++++	+	+	+
DMH1	48		+
Alantolactone									✔	STAT3
SIS3 HCl									✔
Hesperetin								✔		Histamine receptor

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description	Fresolimumab (Anti-TGFb1) is a pan-specific, recombinant, fully human monoclonal antibody directed against human transforming growth factor (TGF) beta 1, 2, and 3 with potential antineoplastic activity. MW : 145.5 KD.

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	948564-73-6
Molecular Weight	145.5 kDa
Isotype	Human IgG4SP
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100mMPro-Ac,20mMArg-Ac，pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

* Name Please enter your name.

* Email Please enter your email. Please enter a valid email address.

Phone

* Comments: Please write something to us.